What's Happening?
Click Therapeutics has secured a $50 million Series D strategic investment to commercialize its digital therapeutic, CT-155, aimed at treating schizophrenia. The company has restructured its agreement with Boehringer Ingelheim, which is transferring all
commercial and marketing rights to Click. CT-155 targets the 'negative' symptoms of schizophrenia, such as lack of motivation and social withdrawal, which are not effectively addressed by standard antipsychotic medications. The therapeutic has shown promising results in clinical trials, with significant improvements in symptom severity and a favorable safety profile.
Why It's Important?
The development of CT-155 addresses a critical unmet need in the treatment of schizophrenia, particularly the negative symptoms that significantly impact patients' quality of life. With no FDA-approved treatments specifically for these symptoms, CT-155 offers a novel approach that could transform the standard of care. The investment and commercialization efforts highlight the growing recognition of digital therapeutics as a viable solution in mental health treatment, potentially leading to broader acceptance and integration into healthcare systems.
